Assessment of CYP3A‐mediated drug interaction via cytokine (IL‐6) elevation for mosunetuzumab using physiologically‐based pharmacokinetic modeling
CPT: Pharmacometrics & Systems Pharmacology · 2024
DOI: 10.1002/psp4.13073 ↗Kurz gefasst
Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2024. Verfasst von Yuan Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, California, USA. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP3A, Antineoplastic Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Mosunetuzumab is a CD3/CD20 bispecific antibody. As an on‐target effect, transient elevation of interleukin‐6 (IL‐6) occurs in early treatment cycles. A physiologically‐based pharmacokinetic (PBPK) model was developed to assess potential drug interaction caused by IL‐6 enzyme suppression on cytochrome P450 3A (CYP3A) during mosunetuzumab treatment. The model's performance in predicting IL‐6 CYP3A suppression and subsequent drug–drug interactions (DDIs) was verified using existing clinical data of DDIs caused by chronic and transient IL‐6 elevation. Sensitivity analyses were performed for a complete DDI risk assessment. The IL‐6 concentration‐ and time‐dependent CYP3A suppression during mosunetuzumab treatment was simulated using PBPK model with incorporation of in vitro IL‐6 inhibition data. At clinically approved doses/regimens, the DDI at maximum CYP3A suppression was predicted to be a midazolam maximum drug concentration in plasma (C max ) and area under the plasma drug concentration–time curve (AUC) ratio of 1.17 and 1.37, respectively. At the 95th percentile of IL‐6 concentration level or when gut CYP3A suppression was considered, the predicted DDI risk for mosunetuzumab remained low (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, California, USA.
- Clinical Science, Genentech, Inc., South San Francisco, California, USA.
- Clinical Pharmacology, Genentech, Inc., South San Francisco, California, USA.
ORCID-Profile: Yuan Chen, Fang Ma, Nicholas Jones, Rong Deng, Chunze Li, Chi-Chung Li
Zitieren
APA
Chen, Y., Ma, F., Jones, N., Deng, R., Li, C., & Li, C. C. (2024). Assessment of CYP3A‐mediated drug interaction via cytokine (IL‐6) elevation for mosunetuzumab using physiologically‐based pharmacokinetic modeling. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.13073
Vancouver
Chen Y, Ma F, Jones N, Deng R, Li C, Li CC. Assessment of CYP3A‐mediated drug interaction via cytokine (IL‐6) elevation for mosunetuzumab using physiologically‐based pharmacokinetic modeling. CPT: Pharmacometrics & Systems Pharmacology. 2024. doi:10.1002/psp4.13073
BibTeX
@article{Chen2024,
author = {Chen, Yuan and Ma, Fang and Jones, Nicholas and Deng, Rong and Li, Chunze and Li, Chi-Chung},
title = {Assessment of CYP3A‐mediated drug interaction via cytokine (IL‐6) elevation for mosunetuzumab using physiologically‐based pharmacokinetic modeling},
journal = {CPT: Pharmacometrics & Systems Pharmacology},
year = {2024},
doi = {10.1002/psp4.13073}
}
EUVIMED